2014

Antifungals Market to 2017 - Generic Erosion of Major Polyenes, Azoles, Allylamines and Echinocandins to Slow Value Growth

NEW YORK, Feb. 7, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antifungals Market to 2017 - Generic Erosion of Major Polyenes, Azoles, Allylamines and Echinocandins to Slow Value Growth

http://www.reportlinker.com/p0751386/Antifungals-Market-to-2017---Generic-Erosion-of-Major-Polyenes-Azoles-Allylamines-and-Echinocandins-to-Slow-Value-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Antifungals Market to 2017 - Generic Erosion of Major Polyenes, Azoles, Allylamines and Echinocandins to Slow Value Growth

Summary GBI Research, the leading business intelligence provider has released its latest research "Antifungals Market to 2017 - Generic Erosion of Major Polyenes, Azoles, Allylamines and Echinocandins to Slow Value Growth", which provides an insight into antifungals sales and price forecasts until 2017. The report examines the global antifungal therapies, treatment usage patterns and treatment flow algorithm. In addition, the geographical distribution of antifungal therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the Research and Development (R&D) pipeline and the potential future blockbusters until 2017 with in-depth analysis of the top three antifungal therapeutic indications, namely aspergillosis, dermatophytosis and candidiasis. Furthermore, it also includes the market forecasts and treatment usage patterns of these three therapeutic indications. The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&A) and licensing agreements involving antifungals therapies is also presented.

In-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by the GBI Research team of experts.

GBI Research analysis shows that the global antifungals market was estimated at $9.4 billion in 2010, with a Compound Annual Growth Rate (CAGR) of 2.9% during 2002 and 2010. The antifungals market is dominated by generics. GBI Research forecasts that the market will grow at a CAGR of 1.9% during 2010-2017 to $10.8 billion. The patent expiry of a number of major drugs has paved way for the entry of generics.

GBI Research analysis shows that the R&D pipeline for the antifungals market is not strong as it has become a generic market. Currently, only 38 molecules are in R&D, which indicates that antifungals R&D activity will not be very active for at least the next seven to eight years.

Scope

- Data and analysis on the antifungals market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.- Annualized market data for the antifungals market from 2002-2010 with forecasts to 2017.- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.- The competitive landscape of the global antifungals market including top companies' benchmarking.- Key M&A activities and licensing agreements that took place in 2009, 2010 and 2011 in the antifungals market.

Reasons to buy

- Build effective strategies to launch their pipeline products by identifying potential geographies.- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.- Develop key strategic initiatives by studying the key strategies of top competitors.- Develop market entry and market expansion strategies by identifying the geographic markets poised for strong growth.- Reinforce R&D pipelines by identifying new target mechanisms which can produce safer and more efficacious first-in-class molecules.

Table of Contents

1 Table of Contents1 Table of Contents 31.1 List of Tables 61.2 List of Figures 82 Global Antifungals Market to 2017 - Introduction 102.1 Overview 102.2 GBI Research Report Guidance 113 Global Antifungals Market to 2017 - Market Characterization 123.1 Introduction 123.2 Different Classes of Antifungals 123.3 Forecast for Global Antifungals Market 143.3.1 Revenues 143.3.2 Branded and Generic Market Share 153.3.3 Annual Cost of Treatment (ACT) 163.3.4 Treatment Usage Patterns 173.4 Drivers for the Antifungals Market 233.4.1 Large Patient Population 233.4.2 Increase in Diagnosis Rate 233.5 Barriers for the Antifungals Market 233.5.1 Prominence of Generics in the Market 233.5.2 High Unmet Need in Case of Serious Invasive Fungal Infections 234 Global Antifungals Market - Geographical Landscape 244.1 Revenue Analysis by Geography 244.2 The US 244.2.1 Revenue 244.2.2 Annual Cost of Treatment 264.2.3 Treatment Usage Pattern 274.3 Top Five Countries of Europe 334.3.1 Revenue 334.3.2 Annual Cost of Treatment 354.3.3 Treatment Usage Pattern 364.4 Japan 424.4.1 Revenue 424.4.2 Annual Cost of Treatment 434.4.3 Treatment Usage Pattern 445 Global Antifungals Market - Aspergillosis Therapeutics Market 505.1 Introduction 505.2 Market Forecasts 505.3 Annual Cost of Treatment 525.4 Treatment Usage Patterns 555.4.1 Diseased Population 575.4.2 Treatment Seeking Population 585.4.3 Diagnosed Population 595.4.4 Prescription Population 605.5 Treatment Flow Algorithm 615.5.1 Allergic Bronchopulmonary Aspergillosis 615.5.2 Invasive Aspergillosis 625.6 Branded and Generic Market Share 635.7 Major Marketed Products 645.7.1 Voriconazole (vfend) 645.7.2 Amphotericin B (amphocin) 645.7.3 AmBisome (amphotericin B) liposome for injection 645.7.4 Itraconazole (sporanox) 655.7.5 Caspofungin (cancidas) 655.7.6 Posaconazole (noxafil) 656 Global Antifungals Market - Dermatophytosis Therapeutics Market 666.1 Introduction 666.2 Market Forecasts 666.3 Annual Cost of Treatment 686.3.1 Annual Cost of Treatment for Tinea Cruris 686.3.2 Annual Cost of Treatment for Tinea Unguium (Onychomycosis) 706.3.3 Annual Cost of Treatment for Tinea Pedis 726.3.4 Annual Cost of Treatment for Tinea Capitis 746.3.5 Annual Cost of Treatment for Tinea Corporis 766.4 Treatment Usage Patterns 786.4.1 Diseased Population 806.4.2 Treatment Seeking Population 816.4.3 Diagnosed Population 826.4.4 Prescription Population 836.5 Treatment Flow Algorithm for Dermatophytosis 846.6 Branded and Generic Market Share 856.7 Major Marketed Products 866.7.1 Ketoconazole 2% cream (nizoral) 866.7.2 Clotrimazole 1% cream or lotion (lotrimin) 866.7.3 Econazole 1% cream or lotion (spectazole) 866.7.4 Miconazole 2% cream (monistat) 866.7.5 Terbinafine (lamisil) 876.7.6 Naftifine 1% cream (naftifin) 876.7.7 Griseofulvin 876.7.8 traconazole (sporanox) 876.7.9 Fluconazole (diflucan) 886.7.10 Sertaconazole nitrate cream (ertaczo) 887 Global Antifungals Market - Candidiasis Therapeutics Market 897.1 Introduction 897.2 Market Forecasts 897.3 Annual Cost of Treatment 917.3.1 Annual Cost of Treatment for Vaginal Candidiasis 917.3.2 Annual Cost of Treatment for Cutaneous Candidiasis 937.3.3 Annual Cost of Treatment for Oropharyngeal Candidiasis 947.3.4 Annual Cost of Treatment for Esophageal Candidiasis 957.3.5 Annual Cost of Treatment for Invasive Candidiasis 967.4 Treatment Usage Patterns 977.4.1 Diseased Population 997.4.2 Treatment Seeking Population 1007.4.3 Diagnosed Population 1017.4.4 Prescription Population 1027.5 Treatment Flow Algorithm for Candidiasis 1037.6 Branded and Generic Market Share 1047.7 Major Marketed Products 1057.7.1 Fluconazole 1057.7.2 Itraconazole Oral Solution 1057.7.3 Clotrimazole 1057.7.4 Canestan 1057.7.5 Anidulafungin (eraxis) 1067.7.6 Nystatin Oral Suspension 1067.7.7 Daktarin IV Solution 1068 Global Antifungals Market - Pipeline Analysis 1078.1 Introduction 1078.2 Aspergillosis: Research and Development Pipeline 1088.2.1 Overview 1088.2.2 Phase lll 1088.2.3 Phase ll 1088.2.4 Phase l 1088.2.5 Preclinical 1088.2.6 Discovery 1098.3 Dermatophytosis: Research and Development Pipeline 1098.3.1 Overview 1098.3.2 Phase lll 1098.3.3 Phase ll 1098.3.4 Phase l 1108.3.5 Preclinical 1108.4 Candidiasis: Research and Development Pipeline 1108.4.1 Overview 1108.4.2 Phase lll 1108.4.3 Phase ll 1108.4.4 Phase l 1118.4.5 Preclinical 1118.5 Profiles of Promising Drugs in the Antifungals Market 1118.5.1 Eraxis + Vfend 1118.5.2 Isavuconazole 1128.5.3 NAFT-500 1128.5.4 Fluconazole 1139 Global Antifungals Market - Competitive Landscape 1149.1 Company Profiles 1149.1.1 Ferrer Internacional S.A. 1149.1.2 BioDelivery Sciences International, Inc. 1159.1.3 Pfizer Inc. 1169.1.4 Merck & Co Inc 1179.1.5 Astellas Pharma Inc 11810 Global Antifungals Market - Strategic Consolidations 12010.1 Mergers and Acquisitions 12010.1.1 Overview 12010.1.2 Major Mergers and Acquisitions Deals 12010.1.3 M&A by Year 12010.1.4 M&A by Deal Value 12110.1.5 M&A by Geography 12110.2 Co-Development Deals 12210.2.1 Overview 12210.2.2 Major Co-Development Deals 12210.3 Licensing Deals 12210.3.1 Overview 12210.3.2 Major Licensing Deals 12210.3.3 Licensing Deals by Year 12311 Global Antifungals Market - Appendix 12611.1 Market Definitions 12611.2 Abbreviations 12611.3 Research Methodology 12711.3.1 Coverage 12711.3.2 Secondary Research 12811.3.3 Primary Research 12811.4 Therapeutic Landscape 12911.4.2 Market Size by Geography 13111.5 Geographical Landscape 13111.6 Pipeline Analysis 13211.7 Competitive Landscape 13211.7.1 Expert Panel Validation 13211.8 Contact Us 13211.9 Disclaimer 13211.10 Sources 133

List of Tables Table 1: Antifungals Market to 2017, Different Classes of Antifungals, 2011 12

Table 2: Antifungals Market to 2017, Global, Revenues ($bn), 2002-2010 14

Table 3: Antifungals Market to 2017, Global, Revenues ($bn), 2010-2017 14

Table 4: Antifungals Market to 2017, Global, Annual Cost of Treatment ($), 2002-2010 16

Table 5: Antifungals Market to 2017, Global, Annual Cost of Treatment ($), 2010-2017 16

Table 6: Antifungals Market to 2017, Global, Treatment Usage Patterns, (million), 2002-2010 17

Table 7: Antifungals Market to 2017, Global, Treatment Usage Patterns, (million), 2010-2017 18

Table 8: Antifungals Market to 2017, The US, Revenues ($bn), 2002-2010 25

Table 9: Antifungals Market to 2017, The US, Revenues ($bn), 2010-2017 25

Table 10: Antifungals Market to 2017, The US, Annual Cost of Treatment ($), 2002-2010 26

Table 11: Antifungals Market to 2017, The US, Annual Cost of Treatment ($), 2010-2017 26

Table 12: Antifungals Market to 2017, The US, Treatment Usage Patterns (million), 2002-2010 27

Table 13: Antifungals Market to 2017, The US, Treatment Usage Patterns (million), 2010-2017 28

Table 14: Antifungals Market to 2017, Top Five Countries of Europe, Revenues ($m), 2002-2010 33

Table 15: Antifungals Market to 2017, Top Five Countries of Europe, Revenues ($m), 2010-2017 34

Table 16: Antifungals Market to 2017, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 35

Table 17: Antifungals Market to 2017, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 35

Table 18: Antifungals Market to 2017, Top Five Countries of Europe, Treatment Usage Patterns (million), 2002-2010 36

Table 19: Antifungals Market to 2017, Top Five Countries of Europe, Treatment Usage Patterns (million), 2010-2017 37

Table 20: Antifungals Market to 2017, Japan, Revenues ($m), 2002-2010 42

Table 21: Antifungals Market to 2017, Japan, Revenues ($m), 2010-2017 42

Table 22: Antifungals Market to 2017, Japan, Annual Cost of Treatment ($), 2002-2010 43

Table 23: Antifungals Market to 2017, Japan, Annual Cost of Treatment ($), 2010-2017 43

Table 24: Antifungals Market to 2017, Japan, Treatment Usage Patterns, (million), 2002-2010 44

Table 25: Antifungals Market to 2017, Japan, Treatment Usage Patterns, (million), 2010-2017 45

Table 26: Aspergillosis Therapeutics Market, Global, Revenues ($m), 2002-2010 50

Table 27: Aspergillosis Therapeutics Market, Global, Revenues ($m), 2010 – 2017 50

Table 28: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Allergic Bronchopulmonary Aspergillosis ($), 2002-2010 52

Table 29: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Allergic Bronchopulmonary Aspergillosis ($), 2010-2017 52

Table 30: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Aspergillosis ($), 2002-2010 53

Table 31: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Aspergillosis ($), 2010-2017 53

Table 32: Aspergillosis Therapeutics Market, Global, Factors Influencing Life Threatening Infection, Invasive Aspergillosis, 2011 54

Table 33: Aspergillosis Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2010 55

Table 34: Aspergillosis Therapeutics Market, Global, Treatment Usage Pattern (million), 2010-2017 56

Table 35: Dermatophytosis Therapeutics Market, Global, Revenues ($bn), 2002-2010 66

Table 36: Dermatophytosis Therapeutics Market, Global, Revenues ($bn), 2010-2017 67

Table 37: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Cruris ($), 2002-2010 68

Table 38: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Cruris ($), 2010-2017 68

Table 39: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Unguium ($), 2002-2010 70

Table 40: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Unguium ($), 2010-2017 70

Table 41: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Pedis ($), 2002-2010 72

Table 42: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Pedis ($), 2010-2017 72

Table 43: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Capitis ($), 2002-2010 74

Table 44: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Capitis ($), 2010-2017 74

Table 45: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Corporis ($), 2002-2010 76

Table 46: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Corporis ($), 2010-2017 76

Table 47: Dermatophytosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2010 78

Table 48: Dermatophytosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010-2017 79

Table 49: Candidiasis Therapeutics Market, Global, Revenues ($bn), 2002-2010 89

Table 50: Candidiasis Therapeutics Market, Global, Revenues ($bn), 2010-2017 90

Table 51: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Vaginal Candidiasis ($), 2002-2010 91

Table 52: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Vaginal Candidiasis ($), 2010-2017 91

Table 53: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Cutaneous Candidiasis ($), 2002-2010 93

Table 54: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Cutaneous Candidiasis ($), 2010-2017 93

Table 55: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Oropharyngeal Candidiasis ($), 2002-2010 94

Table 56: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Oropharyngeal Candidiasis ($), 2010-2017 94

Table 57: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Esophageal Candidiasis ($), 2002-2010 95

Table 58: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Esophageal Candidiasis ($), 2010-2017 95

Table 59: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Candidiasis ($), 2002-2010 96

Table 60: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Candidiasis ($), 2010-2017 96

Table 61: Candidiasis Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2010 97

Table 62: Candidiasis Therapeutics Market, Global, Treatment Usage Patterns (million), 2010-2017 98

Table 63: Aspergillosis Therapeutics Market, Global, Phase lll, 2011 108

Table 64: Aspergillosis Therapeutics Market, Global, Phase ll, 2011 108

Table 65: Aspergillosis Therapeutics Market, Global, Phase l, 2011 108

Table 66: Aspergillosis Therapeutics Market, Global, Preclinical, 2011 108

Table 67: Aspergillosis Therapeutics Market, Global, Discovery, 2011 109

Table 68: Dermatophytosis Therapeutics Market, Global, Phase lll, 2011 109

Table 69: Dermatophytosis Therapeutics Market, Global, Phase ll, 2011 109

Table 70: Dermatophytosis Therapeutics Market, Global, Phase l, 2011 110

Table 71: Dermatophytosis Therapeutics Market, Global, Preclinical, 2011 110

Table 72: Candidiasis Therapeutics Market, Global, Phase lll, 2011 110

Table 73: Candidiasis Therapeutics Market, Global, Phase ll, 2011 110

Table 74: Candidiasis Therapeutics Market, Global, Phase l, 2011 111

Table 75: Candidiasis Therapeutics Market, Global, Preclinical, 2011 111

List of Figures Figure 1: Antifungals Market to 2017, Global, Revenues ($bn), 2002-2017 14

Figure 2: Antifungals Market to 2017, Global, Branded and Generic Market Share (%), 2010-2017 15

Figure 3: Antifungals Market to 2017, Global, Annual Cost of Treatment ($), 2002-2017 16

Figure 4: Antifungals Market to 2017, Global, Treatment Usage Patterns, (million), 2002-2017 17

Figure 5: Antifungals Market to 2017, Global, Diseased Population (million), 2002-2017 19

Figure 6: Antifungals Market to 2017, Global, Treatment Seeking Population (million), 2002-2017 20

Figure 7: Antifungals Market to 2017, Global, Diagnosed Population (million), 2002-2017 21

Figure 8: Antifungals Market to 2017, Global, Prescription Population (million), 2002-2017 22

Figure 9: Antifungals Market to 2017, The US, Revenues ($bn), 2002-2017 24

Figure 10: Antifungals Market to 2017, The US, Annual Cost of Treatment ($), 2002-2017 26

Figure 11: Antifungals Market to 2017, The US, Treatment Usage Patterns (million), 2002-2017 27

Figure 12: Antifungals Market to 2017, The US, Diseased Population (million), 2002-2017 29

Figure 13: Antifungals Market to 2017, The US, Treatment Seeking Population (million), 2002-2017 30

Figure 14: Antifungals Market to 2017, The US, Diagnosed Population (million), 2002-2017 31

Figure 15: Antifungals Market to 2017, The US, Prescription Population (million), 2002-2017 32

Figure 16: Antifungals Market to 2017, Top Five Countries of Europe, Revenues ($bn), 2002-2017 33

Figure 17: Antifungals Market to 2017, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 35

Figure 18: Antifungals Market to 2017, Top Five Countries of Europe, Treatment Usage Patterns (million), 2002-2017 36

Figure 19: Antifungals Market to 2017, Top Five Countries of Europe, Diseased Population (million), 2002-2017 38

Figure 20: Antifungals Market to 2017, Top Five Countries of Europe, Treatment Seeking Population (million), 2002-2017 39

Figure 21: Antifungals Market to 2017, Top Five Countries of Europe, Diagnosed Population (million), 2002-2017 40

Figure 22: Antifungals Market to 2017, Top Five Countries of Europe, Prescription Population (million), 2002-2017 41

Figure 23: Antifungals Market to 2017, Japan, Revenues ($m), 2002-2017 42

Figure 24: Antifungals Market to 2017, Japan, Annual Cost of Treatment ($), 2002-2017 43

Figure 25: Antifungals Market to 2017, Japan, Treatment Usage Patterns, (million), 2002-2017 44

Figure 26: Antifungals Market to 2017, Japan, Diseased Population (million), 2002-2017 46

Figure 27: Antifungals Market to 2017, Japan, Treatment Seeking Population (million), 2002-2017 47

Figure 28: Antifungals Market to 2017, Japan, Diagnosed Population (million), 2002-2017 48

Figure 29: Antifungals Market to 2017, Japan, Prescription Population (million), 2002-2017 49

Figure 30: Aspergillosis Therapeutics Market, Global, Revenues ($m), 2002-2017 50

Figure 31: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Allergic Bronchopulmonary Aspergillosis ($), 2002-2017 52

Figure 32: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Aspergillosis ($), 2002-2017 53

Figure 33: Aspergillosis Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2017 55

Figure 34: Aspergillosis Therapeutics Market, Global, Diseased Population (million), 2002-2017 57

Figure 35: Aspergillosis Therapeutics Market, Global, Treatment Seeking Population (million), 2002-2017 58

Figure 36: Aspergillosis Therapeutics Market, Global, Diagnosed Population (million), 2002-2017 59

Figure 37: Aspergillosis Therapeutics Market, Global, Prescription Population (million), 2002-2017 60

Figure 38: Aspergillosis Therapeutics Market, Global, Treatment Flow Algorithm for Allergic Bronchopulmonary Aspergillosis, 2011 61

Figure 39: Aspergillosis Therapeutics Market, Global, Treatment Flow Algorithm for Invasive Aspergillosis, 2011 62

Figure 40: Aspergillosis Therapeutics Market, Global, Branded and Generic Market Share (%), 2010-2017 63

Figure 41: Dermatophytosis Therapeutics Market, Global, Revenues ($bn), 2002-2017 66

Figure 42: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Cruris ($), 2002-2017 68

Figure 43: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Unguium ($), 2002-2017 70

Figure 44: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Pedis ($), 2002-2017 72

Figure 45: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Capitis ($), 2002-2017 74

Figure 46: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Corporis ($), 2002-2017 76

Figure 47: Dermatophytosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2017 78

Figure 48: Dermatophytosis Therapeutics Market, Global, Diseased Population (million), 2002-2017 80

Figure 49: Dermatophytosis Therapeutics Market, Global, Treatment Seeking Population (million), 2002-2017 81

Figure 50: Dermatophytosis Therapeutics Market, Global, Diagnosed Population (million), 2002-2017 82

Figure 51: Dermatophytosis Therapeutics Market, Global, Prescription Population (million), 2002-2017 83

Figure 52: Dermatophytosis Therapeutics Market, Global, Treatment Flow Algorithm, 2011 84

Figure 53: Dermatophytosis Therapeutics Market, Global, Branded and Generic Market Share (%), 2010-2017 85

Figure 54: Candidiasis Therapeutics Market, Global, Revenues ($bn), 2002-2017 89

Figure 55: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Vaginal Candidiasis ($), 2002-2017 91

Figure 56: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Cutaneous Candidiasis ($), 2002-2017 93

Figure 57: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Oropharyngeal Candidiasis ($), 2002-2017 94

Figure 58: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Esophageal Candidiasis ($), 2002-2017 95

Figure 59: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Candidiasis ($), 2002-2017 96

Figure 60: Candidiasis Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2017 97

Figure 61: Candidiasis Therapeutics Market, Global, Diseased Population (million), 2002-2017 99

Figure 62: Candidiasis Therapeutics Market, Global, Treatment Seeking Population (million), 2002-2017 100

Figure 63: Candidiasis Therapeutics Market, Global, Diagnosed Population (million), 2002-2017 101

Figure 64: Candidiasis Therapeutics Market, Global, Prescription Population (million), 2002-2017 102

Figure 65: Candidiasis Therapeutics Market, Global, Treatment Flow Algorithm, 2011 103

Figure 66: Candidiasis Therapeutics Market, Global, Branded and Generic Market Share (%), 2010-2017 104

Figure 67: Antifungals Market to 2017 to 2017, Global, Pipeline Analysis, 2011 107

Figure 68: Antifungals Market to 2017, SWOT Analysis - Ferrer Internacional SA 114

Figure 69: Antifungals Market to 2017, SWOT Analysis - BioDelivery Sciences International Inc 116

Figure 70: Antifungals Market to 2017, SWOT Analysis - Pfizer Inc 117

Figure 71: Antifungals Market to 2017, SWOT Analysis – Merck & Co Inc 118

Figure 72: Antifungals Market to 2017, SWOT Analysis – Astellas Pharma Inc 119

Figure 73: Antifungals Therapeutics Market, Global, M&A by Year, 2009-2011 120

Figure 74: Antifungals Therapeutics Market, Global, M&A by Deal Value, 2009-2011 121

Figure 75: Antifungals Therapeutics Market, Global, M&A by Geography, 2009 -2011 121

Figure 76: Antifungals Therapeutics Market, Global, Licensing Deals by Year, 2009-2011 123

Figure 77: Antifungals Therapeutics Market, Global, Licensing Deals by Deal Value, 2009-2011 124

Figure 78: Antifungals Therapeutics Market, Global, Licensing Deals by Geography, 2009-2011 125

Figure 79: GBI Research Market Forecasting Model 131

Companies Mentioned Ferrer Internacional S.A.

BioDelivery Sciences International, Inc.

Pfizer Inc.

Merck & Co Inc

Astellas Pharma Inc

To order this report:Drug_and_Medication Industry: Antifungals Market to 2017 - Generic Erosion of Major Polyenes, Azoles, Allylamines and Echinocandins to Slow Value Growth

Contact Clare: clare@reportlinker.com

US:(339) 368 6001

Intl:+1 339 368 6001

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.